On this site you can find recent news about Profil. You can read more about Profil and our work as clinical research organization. Furthermore, we will discuss interesting topics that are of high interest to pharmaceutical or technology companies innovating in the diabetes field.
For any questions or comments, please feel free to contact us using the contact button on the right.
August 21, 2019
Introduction The euglycemic, hyperinsulinemic glucose clamp is the gold standard for the determination of pharmacokinetic and pharmacodynamic (PK/PD) effects of new anti-diabetic drugs, in particular
August 7, 2019
Profil continues the successful series of scientific webinars. On September 4th, 2019 we will air our free webinar on early phase obesity research. The session is presented by PD Dr. Leona
July 23, 2019
Dear all, Greetings from Germany! I am happy to share with you the newest edition of "Profil World" - our newsletter filled with information about clinical research in diabetes and obesity.
July 16, 2019
Dual-hormone artificial pancreas systems use insulin and glucagon to control glucose in patients with diabetes - a dream is about to come true Insulin-only closed-loop AP systems hold promise for
July 2, 2019
Dear all, It is my great honour and pride to present the Profil Science Report 2018. Altogether, Profil’s scientific experts published 29 scientific publications (cumulated impact factor of > 150)
June 18, 2019
The impact of different study populations in glucose clamp studies Over the last decade, the euglycemic clamp technique has evolved to the reference method for assessing time action profiles of
June 4, 2019
People suffering from Diabetes Mellitus can develop both macrovascular and microvascular complications. Retinopathy, nephropathy and neuropathy are the main microvascular complications occurring in
May 21, 2019
Long-acting insulins have been developed for patients with diabetes to provide a basal insulin cover during the day and night. The first slow-release formulations used protamine and/or zinc to